Organovo Holdings, Inc. (0R02.L)
USD 0.38
(-3.43%)
USD 0.38
(-3.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.5 Million USD | 88.83% |
| 2022 | -13.49 Million USD | 49.06% |
| 2021 | -26.49 Million USD | 29.1% |
| 2020 | -37.36 Million USD | -36.58% |
| 2019 | -27.35 Million USD | 25.0% |
| 2018 | -36.47 Million USD | 16.58% |
| 2017 | -43.72 Million USD | 30.32% |
| 2016 | -62.75 Million USD | -1.06% |
| 2015 | -62.09 Million USD | -23.84% |
| 2014 | -50.13 Million USD | -4.12% |
| 2013 | -48.15 Million USD | -225.57% |
| 2012 | -14.79 Million USD | 0.0% |
| 2010 | -1775.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.9 Million USD | -225.28% |
| 2023 FY | -1.5 Million USD | 88.83% |
| 2023 Q2 | -6.01 Million USD | 33.55% |
| 2023 Q1 | -9.04 Million USD | 32.95% |
| 2023 Q4 | -1.5 Million USD | 60.28% |
| 2023 Q3 | -3.79 Million USD | 36.9% |
| 2022 Q1 | -13.47 Million USD | 49.13% |
| 2022 FY | -13.49 Million USD | 49.06% |
| 2022 Q4 | -13.49 Million USD | 26.23% |
| 2022 Q3 | -18.29 Million USD | -62.41% |
| 2022 Q2 | -11.26 Million USD | 16.41% |
| 2021 Q1 | -36 Million USD | 3.63% |
| 2021 Q2 | -33.79 Million USD | 6.16% |
| 2021 FY | -26.49 Million USD | 29.1% |
| 2021 Q4 | -26.49 Million USD | 5.38% |
| 2021 Q3 | -27.99 Million USD | 17.14% |
| 2020 Q2 | -17.65 Million USD | 28.77% |
| 2020 FY | -37.36 Million USD | -36.58% |
| 2020 Q1 | -24.78 Million USD | 9.39% |
| 2020 Q3 | -18.83 Million USD | -6.68% |
| 2020 Q4 | -37.36 Million USD | -98.36% |
| 2019 Q4 | -27.35 Million USD | 10.21% |
| 2019 Q1 | -30.66 Million USD | 15.93% |
| 2019 Q2 | -25.73 Million USD | 16.08% |
| 2019 Q3 | -30.46 Million USD | -18.38% |
| 2019 FY | -27.35 Million USD | 25.0% |
| 2018 Q3 | -35.22 Million USD | 5.7% |
| 2018 Q2 | -37.35 Million USD | 5.7% |
| 2018 Q1 | -39.61 Million USD | 9.41% |
| 2018 Q4 | -36.47 Million USD | -3.56% |
| 2018 FY | -36.47 Million USD | 16.58% |
| 2017 FY | -43.72 Million USD | 30.32% |
| 2017 Q4 | -43.72 Million USD | 7.63% |
| 2017 Q3 | -47.33 Million USD | 6.69% |
| 2017 Q2 | -50.73 Million USD | 7.72% |
| 2017 Q1 | -54.97 Million USD | 12.39% |
| 2016 Q1 | -53.53 Million USD | 13.77% |
| 2016 Q4 | -62.75 Million USD | 10.35% |
| 2016 Q3 | -69.99 Million USD | -35.33% |
| 2016 Q2 | -51.72 Million USD | 3.39% |
| 2016 FY | -62.75 Million USD | -1.06% |
| 2015 FY | -62.09 Million USD | -23.84% |
| 2015 Q4 | -62.09 Million USD | 11.33% |
| 2015 Q3 | -70.02 Million USD | 8.9% |
| 2015 Q2 | -76.86 Million USD | 10.62% |
| 2015 Q1 | -85.99 Million USD | -71.53% |
| 2014 Q2 | -54.37 Million USD | -21.15% |
| 2014 FY | -50.13 Million USD | -4.12% |
| 2014 Q4 | -50.13 Million USD | -0.24% |
| 2014 Q1 | -44.88 Million USD | 6.79% |
| 2014 Q3 | -50.01 Million USD | 8.02% |
| 2013 Q2 | -53.33 Million USD | -315.82% |
| 2013 Q3 | -49.8 Million USD | 6.63% |
| 2013 FY | -48.15 Million USD | -225.57% |
| 2013 Q4 | -48.15 Million USD | 3.31% |
| 2013 Q1 | -12.82 Million USD | 17.79% |
| 2012 Q1 | -8.46 Million USD | 18.19% |
| 2012 Q3 | -14.79 Million USD | -93.43% |
| 2012 Q2 | -7.64 Million USD | 9.72% |
| 2012 Q4 | -15.6 Million USD | -5.5% |
| 2012 FY | -14.79 Million USD | 0.0% |
| 2011 Q1 | -1775.00 USD | 94.4% |
| 2011 Q2 | -1128.00 USD | 36.45% |
| 2011 Q3 | 8747.00 USD | 875.44% |
| 2011 Q4 | -10.35 Million USD | -118454.94% |
| 2010 FY | -1775.00 USD | 0.0% |
| 2010 Q4 | -31.7 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 100.932% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 135.21% |
| Codexis, Inc. | -43.27 Million USD | 96.517% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 98.157% |